Skip to main content

Articles

Page 7 of 13

  1. Lynch syndrome is one of the most common hereditary cancer syndromes and is characterized by the development of many cancers, such as colorectal cancer (CRC), endometrial cancer, ovarian cancer, stomach cancer...

    Authors: Xi Li, Guodong Liu and Wei Wu
    Citation: Experimental Hematology & Oncology 2021 10:37
  2. Tumor-associated macrophages (TAMs) promote key processes in the modulation of tumor microenvironment (TME). However, the clinical significance of heterogeneous subpopulations of TAMs in hepatocellular carcino...

    Authors: Nan Xiao, Xiaodong Zhu, Kangshuai Li, Yifan Chen, Xuefeng Liu, Bin Xu, Ming Lei, Jiejie Xu and Hui-Chuan Sun
    Citation: Experimental Hematology & Oncology 2021 10:36
  3. N6-methyladenosine (m6A) modification, as the most abundant RNA modification, widely participates in the physiological process and is involved in multiple disease progression, especially cancer. YTH N6-methyladen...

    Authors: Xiangyuan Luo, Mengdie Cao, Fan Gao and Xingxing He
    Citation: Experimental Hematology & Oncology 2021 10:35
  4. The 2016 World Health Organization (WHO) classification introduced nodal lymphomas of T follicular helper (Tfh) cell origin, such as angioimmunoblastic T-cell lymphoma (AITL), follicular peripheral T-cell lymp...

    Authors: Sang Eun Yoon, Junhun Cho, Yeon Jeong Kim, Young Hyeh Ko, Woong-Yang Park, Seok Jin Kim and Won Seog Kim
    Citation: Experimental Hematology & Oncology 2021 10:33
  5. Primary cutaneous gamma-delta T-cell lymphoma (PCGD-TCL) is a very rare lymphoma with an aggressive clinical course and a dismal outcome. The prognosis is linked to a pronounced resistance to chemotherapy and ...

    Authors: Sophie Voruz, Laurence de Leval and Anne Cairoli
    Citation: Experimental Hematology & Oncology 2021 10:32
  6. Tumor-associated macrophages (TAMs) are abundant in the tumor microenvironment (TME). However, their contribution to the immunosuppressive status of the TME remains unclear.

    Authors: Linbang Wang, Tao He, Jingkun Liu, Jiaojiao Tai, Bing Wang, Zhiyu Chen and Zhengxue Quan
    Citation: Experimental Hematology & Oncology 2021 10:31
  7. Tirabrutinib (ONO/GS-4059; Ono Pharmaceutical) is a newly developed drug that selectively and irreversibly inhibits Bruton’s tyrosine kinase (BTK) and has been approved in Japan for treating relapsed/refractor...

    Authors: Yoshiko Okita, Rieko Kano-Fujiwara, Shin-Ichi Nakatsuka, Keiichiro Honma and Manabu Kinoshita
    Citation: Experimental Hematology & Oncology 2021 10:29
  8. The evasion of apoptosis through dysregulated Bcl-2 family members is a hallmark of leukaemia stem cells (LSCs) in acute myeloid leukaemia (AML). Therefore, targeting Bcl-2 with venetoclax has been suggested a...

    Authors: Hyunsoo Cho, Ji Eun Jang, Ju-In Eom, Hoi-Kyung Jeung, Haerim Chung, Jin Seok Kim, June-Won Cheong and Yoo Hong Min
    Citation: Experimental Hematology & Oncology 2021 10:28
  9. The receptor tyrosine kinase FLT3 with internal tandem duplications within the juxtamembrane domain (FLT3-ITD) is a poor prognostic factor; however, the prognostic significance of missense mutation in the tyrosin...

    Authors: Wei Guan, Lei Zhou, Yan Li, Erna Yang, Yangyang Liu, Na Lv, Lin Fu, Yi Ding, Nan Wang, Nan Fang, Qian Liu, Binan Wang, Fuwei Li, Juan Zhang, Maoquan Wang, Lili Wang…
    Citation: Experimental Hematology & Oncology 2021 10:27
  10. Aberrant DNA methylation is often related to the diagnosis, prognosis, and therapeutic response of acute myeloid leukemia (AML); however, relevant studies on the relationship between bone marrow myeloblast per...

    Authors: Erna Yang, Desheng Gong, Wei Guan, Jieying Li, Xuefeng Gao, Yonghui Li and Li Yu
    Citation: Experimental Hematology & Oncology 2021 10:26
  11. Proprotein convertase subtilisin/kexin type 9 (PCSK9), one of the key enzymes in the process of lipid transport, is involved in the disease progression of various types of tumors. This article is to study the ...

    Authors: Shi-Zhe Zhang, Xiao-Dong Zhu, Long-Hai Feng, Xiao-Long Li, Xue-Feng Liu, Hui-Chuan Sun and Zhao-You Tang
    Citation: Experimental Hematology & Oncology 2021 10:25
  12. BM-MSCs play an important role in cancer development through the release of cytokines or exosomes. Studies have shown that extracellular exosomes derived from BM-MSCs are a key pro-invasive factor. However, ho...

    Authors: Tianxin Lyu, Yinuo Wang, Ding Li, Hui Yang, Bin Qin, Wenli Zhang, Zhiyue Li, Cheng Cheng, Binglei Zhang, Rongqun Guo and Yongping Song
    Citation: Experimental Hematology & Oncology 2021 10:24
  13. VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a newly-described adult-onset inflammatory syndrome characterized by vacuoles in myeloid and erythroid precursor cells and somatic m...

    Authors: Huijun Huang, Wenjun Zhang, Wenyu Cai, Jinqin Liu, Huijun Wang, Tiejun Qin, Zefeng Xu, Bing Li, Shiqiang Qu, Lijuan Pan, Gang Huang, Robert Peter Gale and Zhijian Xiao
    Citation: Experimental Hematology & Oncology 2021 10:23
  14. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Roberto Crocchiolo, Clara Cesana, Debora Girgenti, Giambattista Bertani, Claudia Barba, Giuseppa Liga, Ursula Ferri, Lara Crucitti, Giovanni Grillo, Silvano Rossini and Roberto Cairoli
    Citation: Experimental Hematology & Oncology 2021 10:22

    The original article was published in Experimental Hematology & Oncology 2021 10:14

  15. Tumor mutation burden (TMB) as estimated by cancer gene panels (CGPs) has been confirmed to be associated with prognosis and is effective in predicting clinical benefit from immune checkpoint blockade (ICB) in...

    Authors: Cunte Chen, Sichu Liu, Xinmiao Jiang, Ling Huang, Feili Chen, Xiaojun Wei, Hanguo Guo, Yang Shao, Yangqiu Li and Wenyu Li
    Citation: Experimental Hematology & Oncology 2021 10:20
  16. Immunotherapy, especially anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) treatment has significantly improved the survival of non-small cell lung cancer (NSCLC) patients. Howe...

    Authors: Mengke Niu, Ming Yi, Ning Li, Suxia Luo and Kongming Wu
    Citation: Experimental Hematology & Oncology 2021 10:18
  17. Hepatocellular carcinoma (HCC) is one of the common cancers that are very aggressive. The secreted cytokine transforming growth factor-β (TGF-β) promotes cancer metastasis by multiple mechanisms such as epithe...

    Authors: Shu Yang, Hongying Zhang, Hua Yang, Jin Zhang, Jiao Wang, Ting Luo, Yangfu Jiang and Hui Hua
    Citation: Experimental Hematology & Oncology 2021 10:17
  18. Cytokine release syndrome (CRS) is the most common toxicity induced by chimeric antigen receptor (CAR) T cell therapy. At present, anti-IL-6 agents including tocilizumab and siltuximab have been applied in the...

    Authors: Lina Zhang, Shuai Wang, Ji Xu, Run Zhang, Han Zhu, Yujie Wu, Liying Zhu, Jianyong Li and Lijuan Chen
    Citation: Experimental Hematology & Oncology 2021 10:16
  19. Belinostat is a histone deacetylase inhibitor approved for relapsed refractory peripheral T-cell lymphoma (PTCL). The primary objective of this study was to determine the maximum tolerated dose (MTD) of belino...

    Authors: Patrick B. Johnston, Amanda F. Cashen, Petros G. Nikolinakos, Anne W. Beaven, Stefan Klaus Barta, Gajanan Bhat, Steven J. Hasal, Sven De Vos, Yasuhiro Oki, Changchun Deng and Francine M. Foss
    Citation: Experimental Hematology & Oncology 2021 10:15
  20. The aim of the present study was to evaluate the circulating T regulatory cells (Tregs) in patients undergoing extracorporeal photopheresis (ECP) for the prevention of chronic graft-versus-host disease (GvHD) ...

    Authors: Roberto Crocchiolo, Clara Cesana, Debora Girgenti, Giambattista Bertani, Claudia Barba, Giuseppa Liga, Ursula Ferri, Lara Crucitti, Giovanni Grillo, Silvano Rossini and Roberto Cairoli
    Citation: Experimental Hematology & Oncology 2021 10:14

    The Correction to this article has been published in Experimental Hematology & Oncology 2021 10:22

  21. Cancer stem cells (CSCs) are a small group of cancer cells, which contribute to tumorigenesis and cancer progression. Cancer cells undergoing epithelial-to-mesenchymal transition (EMT) acquire the chemoresista...

    Authors: Bing Dong, Shiyu Li, Shuangli Zhu, Ming Yi, Suxia Luo and Kongming Wu
    Citation: Experimental Hematology & Oncology 2021 10:12
  22. Hematologic malignancies (HMs) are a heterogeneous group of cancers that comprise diverse subgroups of neoplasms. So far, despite the major epidemiologic concerns about the quality of care, limited data are av...

    Authors: Mohammad Keykhaei, Masood Masinaei, Esmaeil Mohammadi, Sina Azadnajafabad, Negar Rezaei, Sahar Saeedi Moghaddam, Nazila Rezaei, Maryam Nasserinejad, Mohsen Abbasi-Kangevari, Mohammad-Reza Malekpour, Seyyed-Hadi Ghamari, Rosa Haghshenas, Kamyar Koliji, Farzad Kompani and Farshad Farzadfar
    Citation: Experimental Hematology & Oncology 2021 10:11
  23. Arsenic trioxide [ATO, inorganic arsenite (iAsIII) in solution] plays an important role in the treatment of acute promyelocytic leukemia (APL). However, the long-term adverse effects (AEs) and the retention of ar...

    Authors: Yu Zheng, Yuan-Fei Mao, Hui-Jin Zhao, Li Chen, Li-Ning Wang, Yun-Xiang Zhang, Jiong Hu, Jun-Min Li, Xiao-Yang Li and Hong-Ming Zhu
    Citation: Experimental Hematology & Oncology 2021 10:10
  24. Acute myeloid leukemia (AML) with the t(8;21)(q22;q22) chromosomal translocation is among the most common subtypes of AML and produces the AML1-ETO (RUNX1-ETO, RUNX1-RUNX1T1) oncogenic fusion gene. AML1-ETO funct...

    Authors: Daniel T. Johnson, Amanda G. Davis, Jie-Hua Zhou, Edward D. Ball and Dong-Er Zhang
    Citation: Experimental Hematology & Oncology 2021 10:8
  25. Fms-related tyrosine kinase 3 (FLT3) receptor serves as a prognostic marker and therapeutic target in acute myeloid leukemia (AML). Approximately one-third of AML patients carry mutation in FLT3, associated wi...

    Authors: Emma Rörby, Jörgen Adolfsson, Erik Hultin, Thomas Gustafsson, Kourosh Lotfi, Jörg Cammenga and Jan-Ingvar Jönsson
    Citation: Experimental Hematology & Oncology 2021 10:7
  26. Coronavirus disease 2019 (COVID-19) is associated with coagulation abnormalities which are indicators of higher mortality especially in severe cases.

    Authors: Runhui Zheng, Jing Zhou, Bin Song, Xia Zheng, Ming Zhong, Li Jiang, Chun Pan, Wei Zhang, Jiaan Xia, Nanshan Chen, Wenjuan Wu, Dingyu Zhang, Yin Xi, Zhimin Lin, Ying Pan, Xiaoqing Liu…
    Citation: Experimental Hematology & Oncology 2021 10:6
  27. Coronavirus disease 2019 (COVID-19) is a novel infectious viral disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Two consecutively negative SARS-CoV-2 viral RNA test ( interv...

    Authors: Changqian Bao, Xiandong Tao, Wei Cui, Yuanyuan Hao, Shuaike Zheng, Bin Yi, Tiewen Pan, Ken H. Young and Wenbin Qian
    Citation: Experimental Hematology & Oncology 2021 10:5
  28. Classical Hodgkin lymphoma (cHL) and anaplastic lymphoma kinase-positive, anaplastic large cell lymphoma (ALK+ ALCL) are B and T cell lymphomas respectively, which express the tumour necrosis factor receptor s...

    Authors: Zuoqiao Wu, Mary Nicoll and Robert J. Ingham
    Citation: Experimental Hematology & Oncology 2021 10:4
  29. Multiple myeloma (MM) is a hematological malignancy characterized by the clonal expansion of plasma cells in the bone marrow. To date, this disease is still incurable and novel therapeutic approaches are requi...

    Authors: Samah Elsaadi, Ida Steiro, Pegah Abdollahi, Esten N. Vandsemb, Rui Yang, Tobias S. Slørdahl, Torstein Baade Rø, Eline Menu, Anne-Marit Sponaas and Magne Børset
    Citation: Experimental Hematology & Oncology 2021 10:3
  30. The development of programmed cell death-1 inhibitor (PD-1) has shed light on the treatment of tumors with deficiencies in DNA mismatch repair system or microsatellite instability (dMMR/MSI). However, predicti...

    Authors: Qiao-Xuan Wang, Chun-Hua Qu, Yuan-Hong Gao, Pei-Rong Ding, Jing-Ping Yun, Dan Xie and Mu-Yan Cai
    Citation: Experimental Hematology & Oncology 2021 10:2
  31. Optimal treatment of acute myeloid leukemia (AML) arising in elderly patients remains a challenge. FDA approval of Ivosidenib and Enasidenib, small molecule inhibitors of isocitrate dehydrogenase enzymes (IDH1...

    Authors: Sakshi Jasra, Mohammed Kazemi, Nishi Shah, Jiahao Chen, Karen Fehn, Yanhua Wang, Ioannis Mantzaris, Noah Kornblum, Alejandro Sica, LizaMarie Bachier, Mendel Goldfinger, Kira Gritsman, Ira Braunschweig, Ulrich Steidl, Aditi Shastri and Amit Verma
    Citation: Experimental Hematology & Oncology 2021 10:1
  32. Authors: Ana Muntañola, Guillermo Villacampa, José Ángel Hernández-Rivas, Rosalía Alonso, Fátima Mirás, Santiago Osorio, Mónica Baile, Patricia Baltasar, Javier López Jiménez, Ines Hernandez-Rodriguez, Susana Valenciano, Ana Alfayate, Eva Gimeno, Abelardo Bárez, Ana C. Oliveira, Rosalía Riaza…
    Citation: Experimental Hematology & Oncology 2020 9:37
  33. CD44, a complex transmembrane glycoprotein, exists in multiple molecular forms, including the standard isoform CD44s and CD44 variant isoforms. CD44 participates in multiple physiological processes, and aberra...

    Authors: Hanxiao Xu, Mengke Niu, Xun Yuan, Kongming Wu and Aiguo Liu
    Citation: Experimental Hematology & Oncology 2020 9:36
  34. Studies of the gut microbiota (GM) have demonstrated the close link between human wellness and intestinal commensal bacteria, which mediate development of the host immune system. The dysbiosis, a disruption of...

    Authors: Jifeng Yu, Hao Sun, Weijie Cao, Lijie Han, Yongping Song, Dingming Wan and Zhongxing Jiang
    Citation: Experimental Hematology & Oncology 2020 9:35
  35. CD19-targeted CAR T cells therapy has shown remarkable efficacy in treatment of B cell malignancies. However, relapse of primary disease remains a major obstacle after CAR T cells therapy, and the majority of ...

    Authors: Hao Zhang, Pu Zhao and He Huang
    Citation: Experimental Hematology & Oncology 2020 9:34
  36. Cyclic adenosine monophosphate (cAMP) is the first discovered second messenger, which plays pivotal roles in cell signaling, and regulates many physiological and pathological processes. cAMP can regulate the t...

    Authors: Hongying Zhang, Qingbin Kong, Jiao Wang, Yangfu Jiang and Hui Hua
    Citation: Experimental Hematology & Oncology 2020 9:32
  37. T-cell acute lymphoblastic leukemia (T-ALL) is one of the hematological malignancies. With the applications of chemotherapy regimens and allogeneic hematopoietic stem cell transplantation, the cure rate of T-A...

    Authors: Ruyue Zheng, Menglin Li, Shujuan Wang and Yanfang Liu
    Citation: Experimental Hematology & Oncology 2020 9:31
  38. Outcomes of chronic myeloid leukemia (CML) has been improved dramatically in the past two decades, but survival levels of CML patients varied in regions. Comprehensive epidemiological research is necessary to ...

    Authors: Liqing Ning, Chuanyu Hu, Pingfan Lu, Yimei Que, Xiaojian Zhu and Dengju Li
    Citation: Experimental Hematology & Oncology 2020 9:29
  39. Pancreatic cancer is one of the most common causes of cancer-related deaths worldwide. The two major histological subtypes of pancreatic cancer are pancreatic ductal adenocarcinoma (PDAC), accounting for 90% o...

    Authors: He-Li Gao, Wen-Quan Wang, Xian-Jun Yu and Liang Liu
    Citation: Experimental Hematology & Oncology 2020 9:28
  40. Kidney cancer’s incidence and mortality vary in different regions and countries. To compare and interpret kidney cancer’s burden and change trends in the globe and in different countries, we conducted this stu...

    Authors: Xianguang Bai, Ming Yi, Bing Dong, Xinhua Zheng and Kongming Wu
    Citation: Experimental Hematology & Oncology 2020 9:27
  41. Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by constitutive activity of the tyrosine kinase BCR-ABL1. Although the introduction of tyrosine kinase inhibitors (TKIs) has substa...

    Authors: Theresa Klümper, Henrike Bruckmueller, Tobias Diewock, Meike Kaehler, Sierk Haenisch, Christiane Pott, Oliver Bruhn and Ingolf Cascorbi
    Citation: Experimental Hematology & Oncology 2020 9:26

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 9.4
    5-year Journal Impact Factor: 8.3
    Source Normalized Impact per Paper (SNIP): 1.583
    SCImago Journal Rank (SJR): 2.384

    Speed 2023
    Submission to first editorial decision (median days): 2
    Submission to acceptance (median days): 100

    Usage 2023
    Downloads: 696,150
    Altmetric mentions: 375